Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

6662 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-12

Study Completion Date

2022-01-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PATHFINDER is a prospective, multi-center study in which approximately 6,200 participants will be enrolled. An investigational multi-cancer early detection test, developed by GRAIL, will be ordered by and results returned to a study investigator. In cases with a "signal detected" test result (with a predicted or indeterminate tissue of origin (TOO)), the diagnostic work-up will not be dictated by the protocol, but will instead be coordinated by the ordering and treating medical team at the enrolling sites based on the participant's clinical condition, recommendations by each institution's clinical practices, and in consultation with the study investigator and interdisciplinary care team, as necessary. Additionally, proposed clinical care pathways, developed based on a review of guidelines from the National Comprehensive Cancer Network (NCCN), American College of Radiology (ACR) and other professional organizations, should be referenced by the medical team to determine the diagnostic work-up. The number and types of diagnostic procedures required to achieve diagnostic resolution will be assessed. Performance of multi-cancer early detection test will be evaluated. Additionally, participant-reported outcomes will be collected at several time points to assess participants' perceptions about the multi-cancer early detection test. Participants will be followed for approximately 12 months from the time of enrollment. Cancer status will also be assessed at the 12 month time point.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PATHFINDER 2: a Multi-Cancer Early Detection Study

NCT05155605

Early Detection of Cancer Cancer

ACTIVE_NOT_RECRUITING NA

Pan-tumor MRD Study

NCT06605404

Muscle Invasive Bladder Urothelial Carcinoma Esophageal Cancer Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma +4 more

RECRUITING

Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing

NCT04213326

Early Cancer Detection

COMPLETED

Galleri® in the Medicare Population.

NCT05673018

Cancer

RECRUITING NA

REFLECTION: A Clinical Practice Learning Program for Galleri®

NCT05205967

Early Detection of Cancer Cancer

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Elevated Risk and Non-Elevated Risk Groups

Two cohorts:

1. Elevated risk group (approximately 70% of the total enrollment) on the basis of history of smoking, documented genetic cancer predisposition, or personal history of invasive or hematologic malignancy.
2. Non-elevated risk group (approximately 30% of the total enrollment) with none of the conditions listed in the Elevated Risk Group.

Group Type EXPERIMENTAL

Multi-Cancer Early Detection Test

Intervention Type DEVICE

Blood collection and multi-cancer early detection testing with return of results.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Multi-Cancer Early Detection Test

Blood collection and multi-cancer early detection testing with return of results.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Cohort A: Elevated Risk Group (70% of cohort):

* Age: Participant must be 50 years of age or older at the time of signing the Informed Consent Form (ICF).
* Participants must meet at least one of the criteria below:
* History of smoking at least 100 cigarettes in his or her lifetime
* Documented genetic cancer predisposition, hereditary cancer syndrome, or meeting criteria for germline testing based on current NCCN guidelines
* Personal history of invasive or hematologic malignancy, with definitive treatment completed greater than 3 years prior to enrollment. Adjuvant hormone therapy for cancer is permissible (ie may be ongoing within 3 years or at the time of enrollment).

Cohort B: Non-Elevated Risk Group (30% of cohort):

* Age: Participant must be 50 years of age or older, at the time of signing the Informed Consent Form (ICF).
* None of the conditions described in Cohort A, criteria 2a-c
* For all participants, capable of giving signed and legally effective informed consent

Exclusion Criteria

* Undergoing or referred for diagnostic evaluation due to clinical suspicion for cancer (e.g., referred to a medical or surgical oncologist, or scheduled for biopsy on the basis of a suspicious imaging abnormality).
* Personal history of invasive or hematologic malignancy, diagnosed within the 3 years prior to expected enrollment date, or diagnosed greater than 3 years prior to expected enrollment date and never treated.
* Definitive treatment for invasive or hematologic malignancy within the 3 years prior to expected enrollment date. Adjuvant hormone therapy for cancer is not an exclusion criterion.
* Individuals who will not be able to comply with the protocol procedures.
* Individuals who are not current patients at a participating center.
* Previous or current participation in another GRAIL-sponsored study.
* Previous or current employees or contractors of GRAIL.

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes